(NASDAQ: RYTM) Rhythm Pharmaceuticals's forecast annual revenue growth rate of 69.41% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.55%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.46%.
Rhythm Pharmaceuticals's revenue in 2026 is $189,757,000.On average, 18 Wall Street analysts forecast RYTM's revenue for 2026 to be $20,402,886,803, with the lowest RYTM revenue forecast at $17,719,284,770, and the highest RYTM revenue forecast at $23,694,908,533. On average, 15 Wall Street analysts forecast RYTM's revenue for 2027 to be $37,868,151,228, with the lowest RYTM revenue forecast at $29,109,912,126, and the highest RYTM revenue forecast at $48,476,232,036.
In 2028, RYTM is forecast to generate $64,980,043,112 in revenue, with the lowest revenue forecast at $43,497,569,843 and the highest revenue forecast at $85,356,298,750.